30 results about "Bumetanide" patented technology

The invention relates to a method for preparing bumetanide, which comprises that: 3-amino-4-phenoxy-5-sulfonylaminobenzoic acid and n-butanal are used as raw materials; firstly, the raw materials are subjected to condensation-dehydration reaction in the presence of a boron trihalide ether catalyst to generate 3-butylimine-4-phenoxy-5-sulfonylaminobenzoic acid; and then, the 3-butylimine-4-phenoxy-5-sulfonylaminobenzoic acid is catalyzed by palladium carbon and hydrogenated to form the bumetanide. The method has the advantages of simple operation, short reaction time and low equipment requirement, and is suitable for industrialized production; and the yield of a target product can reach more than 90 percent.

The invention discloses application of bumetanide in inhibition of hepatoma cell transfer. Bumetanide can be used for preparing a medicine which is used for inhibiting hepatoma cell multiplication and / or hepatoma cell attack and / or hepatoma cell transfer, can be used for preparing a medicine which is used for curing hepatoma cells and can be used for preparing a product which is used for reducing phosphorylation NKCC1 protein content in hepatoma cells. The bumetanide can be used for reducing the phosphorylation NKCC1 protein content in hepatoma cells, so that hepatoma cell multiplication, attack and transfer are inhibited. The application has significant value for hepatoma cell cure.

A composite medicine for treating hypertension contains the diuretic chosen from errolon, ethacrynic acid, bumetanide, chlorothiazinde, hydrochlorothiazinde, etc a Ca-contained component chosen from shell, inorganic Ca salt, organic Ca salt, etc, and the pharmacologically acceptable additives.

A composite medicine for treating hypertension contains diuretic, a Ca-contained component and accessory which is acceptable in pharmacy, wherein the weight ratio between the diuretic and the Ca-contained component is in the range of 1:10-2000. The diuretic is chosen from furosemidum, ethacrynic acid, bumetanide, torasemide, hydrochlorothiazinde, chlorothiazide, hygroton, metolazone, quinethazone, triamterene, amiloride, spirolactone or acetazolamide, the Ca-contained component is chosen from shell, keel, inorganic Ca salt, organic Ca salt, etc, wherein the shell comprises concha margaritiferallsta, oyster, concha haliotidis or activative product calcium oxide; inorganic Ca salt and organic Ca salt comprise calcium chloride, Ca carbonate, Ca phosphate, Ca citrate, Ca lactate, Ca gluconate or Ca L-threonate .The composite medicine is capable of decreasing blood pressure by rapidly reducing blood volume, wherein the Ca-contained component can restrain the level of booster factors in body to enhance depressurization effects of the diuretic.

The invention discloses a pharmaceutical co-crystal of gefitinib and bumetanide and a preparation method thereof. A molar ratio of gefitinib to bumetanide in the pharmaceutical co-crystal is 1: 1. Inan X-ray diffraction pattern represented by 2theta, characteristic peaks occur when the value of 2theta is equal to 5.08 + / - 0.2 degrees, 8.88 + / - 0.2 degrees, 10.26 + / - 0.2 degrees, 10.56 + / - 0.2 degrees, 17.78 + / - 0.2 degrees, 19.29 + / - 0.2 degrees, 19.68 + / - 0.2 degrees, 20.04 + / - 0.2 degrees, 21.47 + / - 0.2 degrees and 22.70 + / - 0.2 degrees. Compared with gefitinib technical, the pharmaceuticalco-crystal of the invention has better storage stability, better solubility and dissolution rate. Cytotoxicity experiment results show that the pharmaceutical co-crystal has a better inhibition effect on cancer cells and obviously reduced toxic and side effects on normal cells. The preparation method of the pharmaceutical co-crystal is friendly to environment, stable in yield and easy to industrialize.

The present disclosure provides methods of treating Alzheimer's Disease (AD) and rescuing cognitive deficits associated with AD in a subject having an apoE4 / 4 genotype, by administering a therapeutically effective amount of the loop-diuretic bumetanide to the subject. Also disclosed are kits for performing the method, including one or more doses of a bumetanide formulation; and which may also include instructions for treating a patient having an apoE4 / 4 genotype by administering bumetanide, and / or instructions and reagents for testing / identifying a subject having an apoE4 / 4 genotype.

The present invention relates to a composition comprising ibudilast or a pharmaceutically acceptable salt thereof for use in the treatment of Fragile X Syndrome, wherein the composition does not comprise sulindac or a pharmaceutically acceptable salt thereof or bumetanib or a pharmaceutically acceptable salt thereof.

The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.

The invention relates to an antihypertensive drug composition, which comprises gliguidone and bumetanide. A hypoglycemic drug gliguidone is introduced on the basis of a diuretic antihypertensive drug bumetanide, so that collaborative depressurization is achieved and the effect is significantly strengthened. When a fixed compound is formed, the dosage of various single drugs is reduced, and especially the dosage of the bumetanide is greatly reduced, so that the incidence rate of the side effect of the drug is reduced; and protection of the heart is facilitated while hypertension is treated, the damage of the hypertension to the hearth function is significantly reduced, the gliguidone combined with bumetanide has a significant difference in reverse or reduction of left ventricular hypertrophy, and a collaborative treatment effect is obtained.

The invention discloses the application of bumetanide in inhibiting tumor cell proliferation. The invention provides the application of bumetanide in the preparation of drugs for inhibiting tumor cells. The tumor cells may be lung adenocarcinoma cells, colon cancer cells, leukemia cells, esophageal cancer cells, cervical cancer cells or breast cancer cells. The tumor cells may specifically be A549 cells, HCT116 cells, K562 cells, Eca109 cells, Hela cells, Jurkat cells or MCF7 cells. The invention has great value for the treatment of tumors.

The invention provides a bumetanide freeze-dried powder preparation for injection and a preparation method thereof. The method consists of: weighing 10ml of glycerol and water for injection in a volume ratio of 1:4-2:3, and stirring them to obtain a latent solvent; weighing 0.5g of bumetanide and dissolving it in the latent solvent, conducting filtering to clarity, thus obtaining a solution A; weighing 200g of mannitol, adding water for injection accounting for 80% of the total amount, carrying out stirring and filtering to clarity, thus obtaining a solution B; mixing the solution A and the solution B evenly, then adding the remaining water for injection to a total amount of 2000ml, performing degerming filtering, then subjecting the product to filling into 1000 10ml tube-type bottles respectively according to a dosage of 2.0ml / bottle; subjecting the tube-type bottles to heat preservation for 4h under -45DEG C; conducting vacuum pumping to a vacuum degree of not greater than 20pa, raising the slab temperature to -5DEG C at a rate of 2DEG C / h, and carrying out heat preservation for 18h; raising the slab temperature to 30DEG C at a rate of 7DEG C / h, and carrying out heat preservation for 2h, thus obtaining the bumetanide freeze-dried powder preparation for injection. According to the invention, the product stability is effectively ensured, the content of impurities is reduced, and the re-dissolubility of the product is good.

The present invention is related to baby love male capsules including active ingredients such as fludrocortisone, bumetanide, sodium bicarbonates, sodium chloride, and Licourice extract, inactive ingredients such as gelatin, plasticizers, moisture absorbents, and preservatives.The active ingredients are selected according to ovum wall thickness and cell fragility theories. The present invention leads to a breakthrough in the medical field through which the baby gender can be determined and many chronic diseases can be cured.